---
gsd_state_version: "1.0"
milestone: v0.1
milestone_name: verifiable core before application
progress:
  total_phases: 5
  completed_phases: 1
  total_plans: 7
  completed_plans: 3
current_phase: 2
current_phase_name: clinical-kb
status: ready-for-clinical-review
last_updated: 2026-10-14
---
# State

Phase: 2 of 5 (Clinical knowledge base)
Plan: 1 of 1
Status: Phase 1 complete (software verified), Phase 2 partially prepared.
Last activity: 2026-10-14 - core implemented and verified; official EMA source and one PENDING candidate prepared.

## Completed

GSD Phase 1: plans 01-01, 01-02, 01-03 summarized. Verification passed. 30 top-level tests with race detection, vet, built-binary smoke and audit verification pass. No activated clinical rule. Source-bound approval digests and strict defaults prevent candidates becoming recommendations.

## Next action

Resume Phase 2 plan 02-01: acquire current product-specific SmPC/ChPL for five medicines, resolve regulatory applicability and clinical conditions, obtain pharmacist review and independent gold cases. The existing Pradaxa 75 mg adult contraindication candidate remains PENDING. No reviewer approval invented.

## Decisions and limitations

Architecture revision 3: Go core; no automatic approval. No existing project code or GSD plans found initially. GSD research, planning, plan check, execution and verification performed inline under skill fallback. GSD runtime verified as @opengsd/gsd-core 1.13.0; phase completion command used after passed verification. Clinical validation is a distinct open phase; no full application or completed thesis claimed.

Engineering policy and local audit limitations are documented in README.md. Clinical eligibility and golden cases need human review. API/database/RBAC/ingestion/UI/RAG/evaluation remain phases 3–5. Official Go SDK downloaded into this chat's work directory for reproducible local checks.
